Scholar Rock Holding Corporation
SRRK
Classificação em ações
#3423
Scholar Rock Holding Corporation is a biopharmaceutical firm dedicated to... Scholar Rock Holding Corporation is a biopharmaceutical firm dedicated to discovering and advancing treatments for severe medical conditions by targeting the crucial role of protein growth factor signaling. Their lead therapeutic candidate, Apitegromab, an agent designed to inhibit the activation of latent myostatin, has successfully concluded Phase 3 clinical trials for spinal muscular atrophy (SMA). Another key program, SRK-181, is currently undergoing Phase 1 clinical assessment for tackling cancers that exhibit resistance to established checkpoint inhibitor treatments, including anti-PD-1 or anti-PD-L1 antibody therapies. Beyond these, the company cultivates a robust pipeline of innovative potential therapies, aiming to significantly improve the lives of individuals grappling with various severe ailments, such as neurological muscle conditions, malignancies, and fibrotic disorders. In a strategic partnership, Scholar Rock is collaborating with Gilead Sciences, Inc. to identify and develop targeted inhibitors of transforming growth factor beta (TGF-beta) activation, specifically for addressing fibrotic diseases. Established in 2012, Scholar Rock Holding Corporation operates from its headquarters in Cambridge, Massachusetts.
Preço da ação
$41.58
Valor de mercado
$5.06B
Variação (1 dia)
3.34%
Variação (1 ano)
48.94%
País
US
Negociar Scholar Rock Holding Corporation (SRRK)
Categoria
Healthcare
Lucros da Scholar Rock Holding Corporation (SRRK)
Lucros em Jun 2026 TTM: $-408.59M
De acordo com os últimos relatórios financeiros da Scholar Rock Holding Corporation, os ganhos atuais da empresa são de $-408.59M. Em 2023, a empresa teve ganhos de $-165.79M, uma diminuição em relação a aos ganhos de 2022, que foram de $-134.50M. Os ganhos apresentados nesta página são os ganhos antes de juros e impostos, conhecidos como EBIT.
Histórico de lucros da Scholar Rock Holding Corporation de 2016 a 2026
Lucros no final de cada ano
| Ano | Lucros | Alterar |
|---|---|---|
| 2026 (TTM) | $-408.59M | 65.90% |
| 2024 | $-246.29M | 48.56% |
| 2023 | $-165.79M | 23.26% |
| 2022 | $-134.50M | 2.05% |
| 2021 | $-131.80M | 52.40% |
| 2020 | $-86.48M | 69.57% |
| 2019 | $-51.00M | 3.39% |
| 2018 | $-49.33M | 97.34% |
| 2017 | $-25.00M | 54.22% |
| 2016 | $-16.21M | 0.00% |
Lucros de empresas semelhantes ou concorrentes
| Empresa | Lucros | Diferença de Lucros | País |
|---|---|---|---|
| $5.27B | -1,391.00% |
US
|
|
| $-3.09B | 655.52% |
US
|
|
| $-4.02B | 882.94% |
AU
|
|
| - | - |
CH
|
|
| $1.95B | -577.41% |
NL
|
